Search

Displaying results 1151 - 1160 of 5925 in total
  1. Drug

    Phenoxyethanol

    go.drugbank.com/drugs/DB11304
    ApprovedInvestigational

    Phenoxyethanol (EU), or PE, is the most commonly used globally-approved preservative in personal care formulations. It is very easy to use in various types of formulations and is chemically stable. … It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621].

  2. Drug

    PD-0299685

    go.drugbank.com/drugs/DB15264
    Investigational

    PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).

  3. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous

  4. Drug

    Farnesol

    go.drugbank.com/drugs/DB02509
    Investigational

    (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)

  5. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It will be of major benefit to those patients not responding satisfactorily to diuretics alone.

  6. Drug

    Ezetimibe

    go.drugbank.com/drugs/DB00973
    ApprovedInvestigational

    and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi

    Mixtures: EXOTIB-DUOCategories: P-glycoprotein substrates, Cytochrome P-450 CYP2C8 Inhibitors
  7. Drug

    PF-04620110

    go.drugbank.com/drugs/DB14887
    Investigational

    PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).

  8. Drug

    PF-04634817

    go.drugbank.com/drugs/DB14955
    Investigational

    PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).

  9. Drug

    PF-07038124

    go.drugbank.com/drugs/DB19143
    Investigational

    PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

  10. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

    Synonyms: PD-L1/4-1BB bispecific antibody